Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today reported financial results for the third quarter ended September 30, 2023. “I am proud of the progress made across several of our key pillars in the third quarter which meaningfully moved Hims & Hers one step closer toward our vision of an accessible, personalized platform,” said Andrew Dudum, co-founder and CEO. “Personalization cont.

Hims & Hers Health, Inc. Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Outlook

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the leading health and wellness platform, today announced that its Board of Directors has authorized a share repurchase program of up to $50 million of outstanding Class A common stock over the next two years. Hims & Hers intends to use the program to repurchase shares on a discretionary basis from time to time, subject to general business and market conditions and other investment.

Hims & Hers Health, Inc. Announces $50 Million Share Repurchase Program Authorization

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS), the leading health and wellness platform, today introduced MedMatch, a technology designed to transform healthcare by giving providers a more intelligent and informed way to deliver personalized care to patients with more effective and precise treatments and medications. Currently in Beta, MedMatch deploys artificial intelligence and machine learning against the expansive dataset at t.

Hims & Hers Introduces MedMatch, The Next Generation of Intelligent Diagnostic Services

While HIMS showcases robust performance, its ability to navigate and mitigate associated risks will be pivotal in securing its future success. Major risks revolve around customer service issues, rising customer acquisition costs, and potential challenges in retaining customers due to branding and personalization concerns. With a proactive approach to addressing customer concerns and fine-tuning its operational strategies, Hims & Hers has the potential to overcome these challenges and thrive in the telehealth market.

Hims & Hers: A Promising Company With Resolvable Challenges

Hims & Hers is a potential multi-bagger investment with strong growth potential and an attractive valuation. The company's subscription business model allows for compounding revenue over time, strong customer retention, and strong brand equity. Hims & Hers is growing its market vertically and horizontally, adding new supplements and treatment areas regularly.

Hims & Hers: 3 Reasons To Buy This Potential Growth Stock

Hims & Hers Health offers personalized and customized telehealth services, specializing in niche treatments for hair loss, erectile dysfunction, skincare, acne, and mental health. The company has experienced impressive revenue growth and margins, driven by online sales and a growing subscriber base of over 1.3 million customers. Hims & Hers Health is investing in AI and data analysis to enhance personalized treatments and is exploring new market opportunities, such as weight management.

Hims & Hers: Specialization Is The Secret To Great Growth

Hims & Hers continued to grow at an impressive rate of more than 80% last quarter. The telehealth company has been expanding into more areas of healthcare.

Where Will Hims & Hers Health Be in 5 Years?

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced communications veteran Khobi Brooklyn will further position Hims & Hers at the forefront of personalized healthcare as its Chief Communications Officer. Brooklyn's extensive communications leadership experience includes roles at global brands such as Tesla, Nike, Square and Aurora. In her role as CCO, Brooklyn will strengthen the Hims &.

Hims & Hers Names Khobi Brooklyn As Chief Communications Officer

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter 2023 financial results after the market closes on Monday, November 6, 2023. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, refe.

Hims & Hers to Announce Third Quarter 2023 Financial Results on November 6, 2023

CRISPR Therapeutics

Wall Street analysts have high expectations for two healthcare stocks with very different businesses. CRISPR Therapeutics' next-generation gene therapies could be worth billions, but they need to earn regulatory approval first.

2 Growth Stocks That Can Rocket 98% to 108% Higher, According to Wall Street

Hims & Hers is cutting prices, but profit margins are rising. The company is cash flow positive, with plenty of cash on the balance sheet.

Is Hims & Hers Health Stock a Buy Now?

Enphase Energy

Ford Motor Company

Some companies stand out as genuine contenders for explosive growth and substantial gains in the stock market. The article lists three stocks to buy now that have thrived thanks to their innovative strategies and adaptability in the face of change.

Rocket Stocks: 3 Investments Primed to Skyrocket by Year's End

Ginkgo Bioworks Holdings

Consensus price targets from Wall Street analysts suggest a pair of healthcare stocks can more than double your money. Hims & Hers Health runs an increasingly popular niche telehealth platform where patients can get their prescriptions written and filled.

2 Beaten-Down Growth Stocks That Could Rocket 107% to 127% Higher, According to Wall Street

Hims & Hers Health has found itself in the center of a short seller's reticle lately, which may be contributing to the malaise in its share price. But while the short seller may find Hims & Hers Health's business unattractive, the reality has been, for the last five years, that Hims has executed to virtual perfection. As a reward for such perfect execution, Hims now generates healthy free cash flow, alongside ~$200M in cash, no debt, and 70%+ growth.

Hims & Hers Health: Can't Get Much Better

The healthcare company is demonstrating excellent revenue growth.

Hims and Hers Stock Analysis: Buy or Sell?

Hims & Hers reported strong earnings and raised its full-year guidance, but its stock continues to decline. Hims & Hers is focusing on personalization and expanding into new categories to drive growth. While the risks are evident, the company's growth and valuation make it a speculative "Buy."

Hims & Hers Health: Risks Remain, But Upgrading To Buy

Hims & Hers Health, Inc. is rapidly growing and becoming more profitable, making it a cheaply valued stock with minimal risk. A recent short report questions Hims' ability to turn customer acquisition into profitability, but recent financial data shows promising revenue and gross profit growth. While Hims may not have a strong brand equity or an impenetrable moat, its approach and million paying subscribers make it a compelling investment.

Hims & Hers: Myopic Shorts, Absurdly Cheap

The Beauty Health Company

Beauty stocks have not been pretty this year. Cosmetics retailer Ulta Beauty Inc. NASDAQ: ULTA and Estee Lauder Co. NYSE: EL shares are trading down 12.3% and 38.7%, respectively.

2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally

Hims & Hers managed to grow revenue every year by at least 80%. However, it's still trading below its initial price when became publicly traded via SPAC. The company is targeting lofty growth targets for years to come and has plans to expand in many new markets while maintaining gross profits near 80%. The current valuation is rather low at a P/S of just 1.8. The risk-reward profile for an entry point seems very favourable at the moment.

The Market Is Wrong On Hims & Hers Health

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced Great Place To Work® and Fortune magazine named the company on the 2023 Fortune Best Workplaces in Health Care™ List. The Best Workplaces in Health Care award is based on analysis of survey responses from over 208,000 employees from Great Place To Work Certified™ companies in the healthcare industry. Earning a spot means that Hims & Hers is.

Hims & Hers Named on Fortune Media and Great Place to Work's 2023 Best Workplaces in Health Care List

Hims & Hers Health went public through a SPAC merger a couple of years ago. Since then, the stock is down 60%.

Is This Underrated SPAC Deal Stock a No-Brainer Buy?

The market for weight management could be worth close to $300 billion by the end of the decade. Hims & Hers is planning to launch a weight-loss business by January.

This Fast-Growing Company Is the Latest to Launch a Weight-Loss Business

Hims & Hers Health reported a strong Q2 and raised guidance, but the stock has sold off sharply. The company is expanding into new product categories such as heart health and weight management. We believe HIMS stock is undervalued, and current prices present a buying opportunity.

Hims & Hers: Buying With Both Fists (Double Rating Upgrade)

Q2 Revenue beat analyst estimates by $3M. Gross Margin improved despite price cuts. Management raised guidance by $20M, which also beat estimates by $19M.

Hims & Hers: Divergence Between Fundamentals And Valuation

HIMS & Hers Health is performing well, beating guidance and recording positive developments in most metrics. The company is cash flow positive, debt-free, and experiencing peak popularity among search engine users. My updated DCF model indicates over 3.4x potential from current levels, signaling a buying opportunity.

News for Hims & Hers Health Stock (HIMS)